BDRX
Biodexa Pharmaceuticals Plc
Price Chart
Latest Quote
$3.58
-0.11 (-3.12%)
Current Price
| Previous Close | $3.69 |
| Open | $3.51 |
| Day High | $3.59 |
| Day Low | $3.50 |
| Volume | 10,429 |
Stock Information
Note: Financial values converted from GBP to USD
| Shares Outstanding | 276K |
| Cash Equivalents | $4.30M |
| Net Income | $-5.88M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.08M |
| P/E Ratio | 0.01 |
| EPS (TTM) | $509.89 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-2.86M |
| Income | $-5.88M |
| Book/sh | $138.06 |
| Cash/sh | $11.72 |
| Employees | 11 |
Financial Ratios
| Quick Ratio | 2.41 |
| Current Ratio | 2.41 |
Returns & Margins
| ROA | -40.11% |
| ROE | -42.00% |
Ownership
| Institutional Ownership | 0.37% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | 0.03 |
Analyst Data
| Recommendation | none |
| Target Price | $71.67 |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| SMA200 | $nan |
| RSI | 41.22 |
| ATR | nan |
| Shares Float | 93K |
| Short Float | 0.83% |
| Volatility | 1.28 |
| Rel Volume | 0.22 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| Year | nan% |
| 3 Years | nan% |
| 5 Years | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $nan | 116,615 |
| 2026-10-26 | $3.69 | 40,700 |
| 2026-10-23 | $3.38 | 29,300 |
| 2026-10-22 | $3.31 | 11,400 |
| 2026-10-21 | $3.36 | 30,438 |
| 2026-10-20 | $3.09 | 19,675 |
| 2026-10-19 | $3.13 | 71,875 |
| 2026-10-16 | $3.65 | 78,888 |
| 2026-10-15 | $3.45 | 374,000 |
| 2026-10-14 | $3.88 | 6,655,625 |
| 2026-10-13 | $2.80 | 2,872,875 |
| 2026-10-12 | $3.06 | 33,200 |
| 2026-10-09 | $3.68 | 19,600 |
| 2026-10-08 | $4.19 | 13,238 |
| 2026-10-07 | $4.51 | 18,663 |
| 2026-10-06 | $4.76 | 34,225 |
| 2026-10-05 | $4.91 | 12,900 |
| 2026-10-02 | $4.96 | 23,225 |
| 2026-10-01 | $5.06 | 31,488 |
| 2026-09-30 | $5.25 | 18,438 |
| 2026-09-29 | $5.16 | 17,825 |
| 2026-09-28 | $5.44 | 20,338 |
About Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
đ° Latest News
No news articles available at the moment. Check back later for updates on BDRX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $5,297,792 | $7,271,925 | $5,439,566 | $6,835,904 |
| Cost Of Revenue | $5,297,792 | $7,271,925 | $5,439,566 | $6,835,904 |
| Total Revenue | $0 | $0 | $509,583 | $934,904 |
| Operating Revenue | $0 | $0 | $509,583 | $934,904 |
| Expenses | ||||
| Interest Expense | $306,285 | $220,686 | $54,837 | $70,887 |
| Total Expenses | $11,562,588 | $12,303,557 | $11,228,216 | $12,881,352 |
| Other Income Expense | $3,070,874 | $4,304,038 | $651,357 | $625,945 |
| Net Non Operating Interest Income Expense | $-187,248 | $2,675 | $56,175 | $-32,100 |
| Interest Expense Non Operating | $306,285 | $220,686 | $54,837 | $70,887 |
| Operating Expense | $6,264,796 | $5,031,632 | $5,788,650 | $6,045,448 |
| Other Operating Expenses | $-203,298 | $-41,462 | $-18,725 | $-29,425 |
| General And Administrative Expense | $6,468,094 | $5,073,094 | $5,807,375 | $6,074,873 |
| Selling And Marketing Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,538,527 | $-7,662,472 | $-9,468,081 | $-10,239,812 |
| Net Interest Income | $-187,248 | $2,675 | $56,175 | $-32,100 |
| Interest Income | $119,036 | $223,361 | $111,012 | $38,787 |
| Normalized Income | $-11,559,710 | $-11,786,545 | $-10,084,107 | $-10,804,401 |
| Net Income From Continuing And Discontinued Operation | $-8,538,527 | $-7,662,472 | $-9,468,081 | $-10,239,812 |
| Total Operating Income As Reported | $-11,562,588 | $-12,303,557 | $-10,718,633 | $-11,946,447 |
| Net Income Common Stockholders | $-8,538,527 | $-7,662,472 | $-9,468,081 | $-10,239,812 |
| Net Income | $-8,538,527 | $-7,662,472 | $-9,468,081 | $-10,239,812 |
| Net Income Including Noncontrolling Interests | $-8,538,527 | $-7,662,472 | $-9,468,081 | $-10,239,812 |
| Net Income Continuous Operations | $-8,538,527 | $-7,662,472 | $-9,468,081 | $-10,239,812 |
| Pretax Income | $-8,678,963 | $-7,996,844 | $-10,011,101 | $-11,352,602 |
| Interest Income Non Operating | $119,036 | $223,361 | $111,012 | $38,787 |
| Operating Income | $-11,562,588 | $-12,303,557 | $-10,718,633 | $-11,946,447 |
| Gross Profit | $-5,297,792 | $-7,271,925 | $-4,929,983 | $-5,900,999 |
| Special Income Charges | - | - | - | $0 |
| Net Income Discontinuous Operations | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-66.87 | $-668.74 | $-13374.89 | $-1036553.59 |
| Basic EPS | $-66.87 | $-668.74 | $-13374.89 | $-94.51 |
| Other | ||||
| Tax Effect Of Unusual Items | $49,691 | $179,965 | $35,331 | $61,356 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,190,766 | $-11,740,474 | $-10,229,112 | $-11,448,902 |
| Total Unusual Items | $3,070,874 | $4,304,038 | $651,357 | $625,945 |
| Total Unusual Items Excluding Goodwill | $3,070,874 | $4,304,038 | $651,357 | $625,945 |
| Reconciled Depreciation | $252,785 | $339,722 | $378,509 | $458,759 |
| EBITDA (Bullshit earnings) | $-8,119,893 | $-7,436,436 | $-9,577,755 | $-10,822,957 |
| EBIT | $-8,372,678 | $-7,776,158 | $-9,956,264 | $-11,281,715 |
| Diluted Average Shares | $146,752 | $13,249 | $4,224 | $16,523 |
| Basic Average Shares | $146,752 | $13,249 | $4,224 | $16,523 |
| Diluted NI Availto Com Stockholders | $-8,538,527 | $-7,662,472 | $-9,468,081 | $-10,239,812 |
| Tax Provision | $-140,436 | $-334,372 | $-543,020 | $-1,112,790 |
| Gain On Sale Of Security | $3,070,874 | $4,304,038 | $651,357 | $625,945 |
| Selling General And Administration | $6,468,094 | $5,073,094 | $5,807,375 | $6,074,873 |
| Other Gand A | $6,468,094 | $5,073,094 | $5,807,375 | $6,074,873 |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
| Impairment Of Capital Assets | - | - | - | $0 |
Fetched: 2026-10-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $7,703,934 | $3,579,119 | $2,323,218 | $4,221,574 |
| Total Assets | $24,314,203 | $19,768,080 | $14,099,804 | $7,389,624 |
| Total Non Current Assets | $7,671,834 | $7,984,806 | $4,697,260 | $1,119,478 |
| Goodwill And Other Intangible Assets | $7,550,123 | $7,551,460 | $3,933,554 | $8,025 |
| Other Intangible Assets | $7,550,123 | $7,551,460 | $3,933,554 | $8,025 |
| Current Assets | $16,642,369 | $11,783,274 | $9,402,544 | $6,270,146 |
| Prepaid Assets | $4,931,320 | $8,594,701 | $474,808 | $502,896 |
| Receivables | $296,922 | $956,304 | $941,592 | $1,974,133 |
| Other Receivables | $85,599 | $175,211 | $377,172 | $402,584 |
| Taxes Receivable | $164,511 | $766,381 | $564,420 | $1,131,515 |
| Accounts Receivable | $46,812 | $14,712 | $0 | $440,034 |
| Cash Cash Equivalents And Short Term Investments | $11,414,127 | $2,232,268 | $7,986,144 | $3,793,117 |
| Cash And Cash Equivalents | $11,414,127 | $2,232,268 | $7,986,144 | $3,793,117 |
| Cash Financial | $11,414,127 | $2,232,268 | $7,986,144 | $3,793,117 |
| Debt | ||||
| Total Debt | $81,587 | $972,354 | $620,595 | $834,593 |
| Long Term Debt And Capital Lease Obligation | $0 | $157,824 | $394,559 | $619,257 |
| Current Debt And Capital Lease Obligation | $81,587 | $814,530 | $226,036 | $215,336 |
| Current Debt | - | - | - | $0 |
| Long Term Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $9,060,147 | $8,637,501 | $7,843,033 | $3,160,025 |
| Total Non Current Liabilities Net Minority Interest | $862,680 | $1,904,584 | $394,559 | $618,797 |
| Other Non Current Liabilities | $862,680 | $1,746,760 | - | $-460 |
| Current Liabilities | $8,197,467 | $6,732,917 | $7,448,473 | $2,541,228 |
| Other Current Liabilities | $4,651,785 | $1,231,827 | $5,563,952 | $113,687 |
| Current Deferred Liabilities | $763,706 | $1,963,433 | $0 | $263,485 |
| Payables And Accrued Expenses | $2,700,389 | $2,723,127 | $1,658,486 | $1,671,861 |
| Payables | $212,661 | $1,020,504 | $512,258 | $579,133 |
| Other Payable | $22,737 | $8,025 | $9,362 | $22,737 |
| Total Tax Payable | $60,187 | $66,874 | $82,924 | $102,987 |
| Accounts Payable | $129,736 | $945,604 | $419,971 | $453,409 |
| Equity | ||||
| Common Stock Equity | $15,254,056 | $11,130,579 | $6,256,771 | $4,229,599 |
| Total Equity Gross Minority Interest | $15,254,056 | $11,130,579 | $6,256,771 | $4,229,599 |
| Stockholders Equity | $15,254,056 | $11,130,579 | $6,256,771 | $4,229,599 |
| Other Equity Interest | $1,584,924 | $1,195,715 | $4,623,698 | $2,300,482 |
| Gains Losses Not Affecting Retained Earnings | $70,894,915 | $70,890,903 | $70,890,903 | $70,890,903 |
| Other Equity Adjustments | $70,890,903 | $70,890,903 | $70,890,903 | $70,890,903 |
| Retained Earnings | $-208,391,408 | $-201,190,370 | $-193,624,198 | $-181,010,344 |
| Other | ||||
| Ordinary Shares Number | $302,028,722,528 | $8,942,339,670 | $1,591,046,523 | $7,245,358 |
| Share Issued | $302,028,722,528 | $8,942,339,670 | $1,591,046,523 | $7,245,358 |
| Tangible Book Value | $7,703,934 | $3,579,119 | $2,323,218 | $4,221,574 |
| Invested Capital | $15,254,056 | $11,130,579 | $6,256,771 | $4,229,599 |
| Working Capital | $8,444,902 | $5,050,357 | $1,954,071 | $3,728,918 |
| Capital Lease Obligations | $81,587 | $972,354 | $620,595 | $834,593 |
| Total Capitalization | $15,254,056 | $11,130,579 | $6,256,771 | $4,229,599 |
| Foreign Currency Translation Adjustments | $4,012 | $0 | $0 | $0 |
| Additional Paid In Capital | $132,308,375 | $124,552,279 | $116,003,053 | $111,903,650 |
| Capital Stock | $18,857,250 | $15,682,053 | $8,363,316 | $144,908 |
| Common Stock | $18,857,250 | $15,682,053 | $8,363,316 | $144,908 |
| Long Term Capital Lease Obligation | $0 | $157,824 | $394,559 | $619,257 |
| Current Deferred Revenue | $763,706 | $1,963,433 | $0 | $263,485 |
| Current Capital Lease Obligation | $81,587 | $814,530 | $226,036 | $215,336 |
| Current Accrued Expenses | $2,487,729 | $1,702,623 | $1,146,228 | $1,092,728 |
| Goodwill | $0 | $0 | $0 | $0 |
| Net PPE | $121,711 | $433,346 | $763,706 | $1,111,453 |
| Accumulated Depreciation | $-1,130,178 | $-1,629,061 | $-2,309,843 | $-2,181,444 |
| Gross PPE | $1,251,889 | $2,062,407 | $3,073,549 | $3,292,897 |
| Leases | $70,887 | $70,887 | $70,887 | $70,887 |
| Other Properties | $1,104,766 | $1,873,821 | $2,851,525 | $3,020,049 |
| Machinery Furniture Equipment | $76,237 | $117,699 | $151,136 | $201,961 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | - | - | $0 |
| Current Provisions | - | - | - | $276,860 |
| Buildings And Improvements | - | - | - | $70,887 |
Fetched: 2026-10-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,402,103 | $-17,434,163 | $-9,481,456 | $-9,509,543 |
| Operating Activities | ||||
| Operating Cash Flow | $-7,477,898 | $-16,398,946 | $-9,129,697 | $-9,426,619 |
| Cash Flow From Continuing Operating Activities | $-7,477,898 | $-16,398,946 | $-9,129,697 | $-9,426,619 |
| Operating Gains Losses | $-3,205,960 | $-4,293,338 | $-648,682 | $-608,557 |
| Investing Activities | ||||
| Capital Expenditure | $-924,205 | $-1,035,216 | $-351,759 | $-82,924 |
| Investing Cash Flow | $-779,756 | $-799,818 | $-354,434 | $-294,247 |
| Cash Flow From Continuing Investing Activities | $-779,756 | $-799,818 | $-354,434 | $-294,247 |
| Net Other Investing Changes | - | - | $-105,662 | $-276,860 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $18,389,129 | $11,117,204 | $13,945,993 | $325,010 |
| Financing Cash Flow | $17,439,513 | $11,444,889 | $13,677,157 | $62,862 |
| Cash Flow From Continuing Financing Activities | $17,439,513 | $11,444,889 | $13,677,157 | $62,862 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $18,389,129 | $11,117,204 | $13,945,993 | $325,010 |
| Common Stock Issuance | $18,389,129 | $11,117,204 | $13,945,993 | $325,010 |
| Other | ||||
| Repayment Of Debt | $-329,022 | $-248,773 | $-251,448 | $-238,073 |
| End Cash Position | $11,414,127 | $2,232,268 | $7,986,144 | $3,793,117 |
| Beginning Cash Position | $2,232,268 | $7,986,144 | $3,793,117 | $13,451,122 |
| Effect Of Exchange Rate Changes | $0 | $0 | $0 | $0 |
| Changes In Cash | $9,181,859 | $-5,753,876 | $4,193,026 | $-9,658,004 |
| Interest Paid Cff | $-18,725 | $0 | $-17,387 | $-24,075 |
| Net Issuance Payments Of Debt | $-930,892 | $327,685 | $-251,448 | $-238,073 |
| Net Long Term Debt Issuance | $-930,892 | $327,685 | $-251,448 | $-238,073 |
| Long Term Debt Payments | $-329,022 | $-248,773 | $-251,448 | $-238,073 |
| Interest Received Cfi | $120,374 | $235,398 | $97,637 | $38,787 |
| Net Intangibles Purchase And Sale | $-921,530 | $-1,023,179 | $-316,985 | $0 |
| Purchase Of Intangibles | $-921,530 | $-1,023,179 | $-316,985 | $0 |
| Net PPE Purchase And Sale | $21,400 | $-12,037 | $-29,425 | $-56,175 |
| Sale Of PPE | $24,075 | $0 | $5,350 | $26,750 |
| Purchase Of PPE | $-2,675 | $-12,037 | $-34,775 | $-82,924 |
| Taxes Refund Paid | $945,604 | $172,536 | $1,130,178 | $906,817 |
| Change In Working Capital | $2,295,130 | $-4,996,857 | $-65,537 | $695,494 |
| Change In Payables And Accrued Expense | $-1,221,127 | $2,994,637 | $-276,860 | $476,146 |
| Change In Payable | $-1,221,127 | $2,994,637 | $-276,860 | $476,146 |
| Change In Receivables | $3,516,257 | $-7,991,494 | $488,183 | $9,362 |
| Other Non Cash Items | $187,248 | $-2,675 | $-56,175 | $32,100 |
| Stock Based Compensation | $227,373 | $378,509 | $37,450 | $164,511 |
| Asset Impairment Charge | $498,883 | $0 | $105,662 | $276,860 |
| Deferred Tax | $-140,436 | $-334,372 | $-543,020 | $-1,112,790 |
| Deferred Income Tax | $-140,436 | $-334,372 | $-543,020 | $-1,112,790 |
| Depreciation Amortization Depletion | $252,785 | $339,722 | $378,509 | $458,759 |
| Depreciation And Amortization | $252,785 | $339,722 | $378,509 | $458,759 |
| Amortization Cash Flow | $1,337 | $2,675 | $4,012 | $4,012 |
| Amortization Of Intangibles | $1,337 | $2,675 | $4,012 | $4,012 |
| Depreciation | $251,448 | $337,047 | $374,497 | $454,746 |
| Gain Loss On Investment Securities | $-3,070,874 | $-4,304,038 | $-651,357 | $-625,945 |
| Net Foreign Currency Exchange Gain Loss | $-173,874 | $5,350 | $0 | $-1,337 |
| Gain Loss On Sale Of PPE | $38,787 | $5,350 | $2,675 | $18,725 |
| Net Income From Continuing Operations | $-8,538,527 | $-7,662,472 | $-9,468,081 | $-10,239,812 |
| Issuance Of Debt | - | $576,458 | $0 | $0 |
| Net Short Term Debt Issuance | - | $576,458 | $0 | $0 |
| Short Term Debt Issuance | - | $576,458 | $0 | $0 |
| Change In Other Working Capital | - | - | $-276,860 | $209,986 |
| Long Term Debt Issuance | - | - | - | $0 |
| Net Business Purchase And Sale | - | - | - | - |
| Purchase Of Business | - | - | - | - |
Fetched: 2026-10-24